<DOC>
	<DOC>NCT01845311</DOC>
	<brief_summary>The RESTORE II clinical trial is intended to assess safety and performance of the ReZolve2 Bioresorbable Coronary Scaffold in native coronary arteries.</brief_summary>
	<brief_title>ReZolve2 Clinical Investigation</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>Primary Patient has evidence of myocardial ischemia or a positive functional study Patient has a normal CKMB Target lesion has a visually estimated stenosis of ≥50% and &lt;100% Target lesion is located in a native coronary artery with average reference vessel diameter ≥ 2.75mm and ≤ 3.3mm Target lesion length must be ≤ 14mm Primary Patient has experienced a myocardial infarction (CKMB or Troponin &gt; 5 X ULN) within 72 hours of the procedure Patient has a left ventricular ejection fraction &lt; 30% Patient has unprotected lest main coronary disease with ≥50% stenosis The target vessel is totally occluded (TIMI Flow 0 or 1) Target lesion involves a bifurcation (a lesion with a side branch ≥ 2.0 mm in diameter containing a ≥ 50% stenosis). Target lesion is located within a bypass graft Target lesion has possible or definite thrombus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>